FDA Panel Recommends Nintedanib for Rare Lung Disease FDA Panel Recommends Nintedanib for Rare Lung Disease

Small effect size for primary endpoint in systemic sclerosis-associated interstitial lung disease study, and lack of significant difference between groups for secondary outcomes, were sticking points.Medscape Medical News
Source: Medscape Rheumatology Headlines - Category: Rheumatology Tags: Rheumatology News Source Type: news